GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 392 Shares

Key Points

• CFO Kevin Feeley sold 392 shares on April 29 at an average price of $65.19 for $25,554.48 to cover tax withholding on vested equity; after the sale he still directly owns 34,942 shares (a 1.11% reduction, valued at ≈$2.28M).
• Feeley previously sold 5,706 shares on March 16 at $76.80 and 6,187 shares on March 4 at $78.61, together generating roughly $924,581 in proceeds.
• GeneDx shares recently traded at $65.38 with a market cap of $1.91B, a 50‑day SMA of $71.45 and 200‑day SMA of $107.37; analysts have a consensus rating of Moderate Buy with an average price target of $134.17.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 392 shares of the business's stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the completion of the transaction, the chief financial officer directly owned 34,942 shares of the company's stock, valued at approximately $2,277,868.98. This trade represents a 1.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total value of $438,220.80.
• On Wednesday, March 4th, Kevin Feeley sold 6,187 shares of GeneDx stock. The stock was sold at an average price of $78.61, for a total value of $486,360.07.

GeneDx Stock Performance

Shares of WGS traded up $2.49 on Friday, reaching $65.38. The company's stock had a trading volume of 591,523 shares, compared to its average volume of 727,660. The stock's 50 day simple moving average is $71.45 and its two-hundred day simple moving average is $107.37. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34. The stock has a market capitalization of $1.91 billion, a P/E ratio of -87.17 and a beta of 2.17. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The business had revenue of $120.99 million during the quarter, compared to analysts' expectations of $120.80 million. Research analysts forecast that GeneDx Holdings Corp. will post 0.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Zacks Research downgraded shares of GeneDx from a "strong-buy" rating to a "hold" rating in a report on Friday, April 24th. Canaccord Genuity Group set a $100.00 price objective on shares of GeneDx and gave the stock a "buy" rating in a research note on Monday, April 20th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research report on Monday, February 23rd. Piper Sandler restated an "overweight" rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, BTIG Research dropped their target price on shares of GeneDx from $200.00 to $170.00 and set a "buy" rating for the company in a report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.17.

Institutional Trading of GeneDx

A number of institutional investors and hedge funds have recently bought and sold shares of WGS. Jones Financial Companies Lllp lifted its stake in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of GeneDx in the fourth quarter worth about $27,000. Quarry LP lifted its position in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company's stock worth $32,000 after buying an additional 209 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the fourth quarter worth about $33,000. Finally, Greenline Wealth Management LLC bought a new position in GeneDx during the fourth quarter valued at approximately $33,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.